NeoDynamics AB presents an abstract on preclinical results with its novel biopsy system NeoNavia at the St Gallen International Breast Cancer Conference 2021, which is held March 17-21, 2021 in Vienna.
STOCKHOLM, March 15, 2021 /PRNewswire/ -- NeoDynamics AB (publ) presents an abstract on preclinical results with its novel biopsy system NeoNavia at the St Gallen International Breast Cancer Conference 2021, which is held March 17-21, 2021 in Vienna.
In light of this event, NeoDynamics and Redeye are organizing a parallel digital presentation for the financial markets on Wednesday March 17 at 13.00 - 14.00 CET where CEO Anna Eriksrud and Dr Kai-Uwe Schässburger, Head of Clinical Development & Medical Affairs, will present the results and comment on the launch of the product. The presentation will be followed by a Q&A session led by Redeye’s analyst Oskar Bergman.
Please register to participate at Redeye at the following link: https://www.lyyti.in/Strategy_Update_NeoDynamics_9010
The presentation will be held in English.
The abstract will also be published in the scientific journal The Breast.
For further information, please contact:
Anna Eriksrud, CEO NeoDynamics AB. Phone +46 708 444 966
e-mail: anna.eriksrud@neodynamics.com
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/invitation---neodynamics-presents-preclinical-results-on-march-17-at-13-00-cet-301247135.html
SOURCE NeoDynamics
Company Codes: ISIN:SE0011563410
